Abstract

Inflammatory Breast Cancer (IBC) represents 1-2% of all invasive breast carcinomas and is associated with an underlying ductal or lobular primary tumor [2, 3]. This subtype of breast cancer presents as swelling and redness of the involved breast, with a characteristic peaud'o range look. IBC is a very aggressive subtype of breast cancer conferring a worse prognosis than non-inflammatory breast cancer, with a 5 year overall survival rate of 25.4% vs 31.8% respectively [4]. This is largely due to propensity for distant metastasis and local recurrence. 30% of patients with IBC had metastatic disease at the time of diagnosis compared to 6-10% of patients with non-inflammatory breast cancer [5, 6].